Tag Archives: simvastatin

Introduction A drug–drug interaction (DDI) is a pharmacokinetic (PKI) or pharmacological influence of one medicine on another that differs from the known or anticipated effects of each agent alone. A DDI may result in a change in either drug efficacy or drug toxicity for one or both of the interacting medicines. PKI interactions occur when one medicine alters the absorption, distribution, metabolism, or excretion of another, thus, increasing or decreasing the amount of medicine available to produce its pharmacological effects. Such PKI interactions occurring with one medicine do not necessarily occur uniformly across a group of related med

Introduction Large intervention studies suggest that while lowering low-density lipoprotein cholesterol (LDL-C) is beneficial, it is insufficient to prevent the majority of coronary heart disease (CHD) events. Niacin improves the overall lipid profile, LDL-C and triglycerides (TG) and is the most effective agent for raising high-density lipoprotein cholesterol (HDL-C) levels.1 Co-administration of niacin with a statin offers the potential for additional lipid management, but the use of niacin has been limited due to associated flushing, mediated primarily by prostaglandin D2 (PGD2).2 Flushing of the face and trunk occurs in nearly all patient

Prasugrel lowers events but increases bleeding compared with clopidogrel in PCI patients The new antiplatelet agent, prasugrel, reduced ischaemic events compared with clopidogrel but at the cost of an increase in major bleeding in the TRITON-TIMI 38 trial in acute coronary syndrome (ACS) patients scheduled for percutaneous coronary intervention (PCI). Overall mortality did not differ significantly between the two groups. In the study, which has also been published in the New England Journal of Medicine, prasugrel prevented 23 myocardial infarctions (MIs) for every 1,000 patients treated but caused an excess of six non-CABG (coronary artery by

No content available